Jason Kropp

JASON KROPP advises emerging and growth-stage companies, venture and growth equity investors, and mature private businesses on a wide range of strategic transactions and corporate matters. His practice focuses on the life sciences, biotech, medical device, software, and e-commerce industries, where he counsels clients from formation through exit, including financings, M&A, and other mission-critical deals.

Jason represents both companies and investors in early- and late-stage venture capital and growth financings, often serving as outside general counsel to high-growth private companies. He regularly works with clients navigating complex equity structures, board and governance matters, and strategic transactions across the corporate lifecycle. Jason has advised on more than 500 private company financing transactions, resulting in more than US$32 billion of proceeds.

Jason has been recognized in the 2015–2025 editions of Chambers USA for his work in Corporate/M&A in Massachusetts, with sources describing him as “really phenomenal in the corporate and securities area” and that “he has a great temperament, he’s a great negotiator, and he keeps his cool in situations.” He was named a “Life Sciences Star” by LMG Life Sciences (2023), and as “Venture Capital Attorney of the Year” by LMG Life Sciences in 2022 and shortlisted in 2023. Jason was also recommended in the area of M&A: Middle-Market and Venture Capital and Emerging Companies in the 2018 and 2019 editions of Legal 500 United States, named a Thomson Reuters “Stand-out Lawyer” — independently rated and selected by clients, and selected by peers for inclusion in The Best Lawyers in America® for Corporate Law (2024) and Venture Capital Law (2024).

Prior to attending law school, Jason worked as a legislative and press aide in the office of U.S. Representative William Delahunt, and as a legislative intern in the office of U.S. Representative Gerry Studds.

• Wellington Management in early-, late-stage, and crossover investments, including Attentive, Automattic, Cargo Therapeutics, Cityblock Health, Course Hero, DraftKings, ezCater, Greenlight, Guild Education, HeartFlow, Invuity, Klarna, Olist, Olo, Omada Health, One Kings Lane, Oscar, Patreon, Payoneer, Quince, Redfin, Satsuma Pharmaceuticals, Scale, SeatGeek, Skims, SpotOn, Strata Oncology, Stripe, Synthego, Thriveworks, Tricida, Uber, and UiPath.
• General Catalyst in early-, late-stage, and crossover investments and strategic transactions, including Awardco, Beacon Biosignals, BigCommerce, Capital Rx, Circle, Cityblock Health, ClassPass, Commure, Contrast Security, Dandy, Equip Health, Feedvisor, Fundbox, Guild Education, The Honest Company, Instacart, Julia Computing, Lemonade, Maribel Health, Material Bank, Maven, Maze Therapeutics, NewStore, OM1, Oscar, Outdoor Voices, Overjet, PathAI, Ro, Samsara, Snap, TuneIn, and Warby Parker.
• Private and public companies across of range of matters, including Alethea, Ameresco, Analog Devices, ASICS, Corvia Medical, Cynosure, Embark Veterinary, EqualLogic, Esme Learning Solutions, Exo Therapeutics, GentiBio, ImaginAb, ImmPACT Bio, Jebbit, Kalaris Therapeutics, Karyopharm Therapeutics, Kisbee Therapeutics, Kiva Systems, LINKMedicine, LogRocket, Magnet Biomedicine, Myeloid Therapeutics, Nyansa, PharmaCCX, Respira Therapeutics, Ribometrix, VDyne, and ZeroNorth.
• Financial and strategic investors, including Delta-v Capital, Samsara BioCapital, OrbiMed, RA Capital Management, Novartis Venture Fund, Matrix Partners, New Leaf Venture Partners, and Sofinnova Ventures, among others, in private placement financings.
• Acacia Communications, Ameresco, Accretive Health, Endurance International Group, EverQuote, Eyetech Pharmaceuticals, LogMeIn, and Cynosure in their initial public offerings.
• Numerous issuers in follow-on public offerings.

The above matters were handled prior to joining Sidley.

• Member, Board of Directors, Coaching4Change